PRS25 THE IMPACT TRIAL: IS SINGLE-INHALER TRIPLE THERAPY (FF/UMEC/VI) COST-EFFECTIVE VERSUS DUAL THERAPY WITH INHALED CORTICOSTEROID PLUS LONG-ACTING BETA AGONIST (FF/VI) IN PATIENTS WITH COPD IN SPAIN?
Abstract
Authors
V. Paly L.A. Vallejo-Aparicio M. Schroeder A. Martin J.L. Izquierdo Alonso J.A. Riesco Miranda J.J. Soler Cataluña N. Risebrough C. Abreu C. Biswas A.S. Ismaila